CYP51-IN-25

CYP51-IN-25 (Compoud C52) has a broad-spectrum antifungal activity in Candida albicans (SC 5314) (MIC₈₀ = 0.0625 μg/mL), Candida albicans (CPCC 400616) (MIC₈₀ = 0.0625 μg/mL), Candida tropicalis (CGMCC 2.3739) (MIC₈₀ = 0.0625 μg/mL), Candida parapsilosis (GIM 2.190) (MIC₈₀ = 0.0625 μg/mL), Candida glabrata (Clinical isolation) (MIC₈₀ = 0.0125 μg/mL) (MFC = 0.5 μg/mL), Candida krusei (AS 2.1045) (MIC₈₀ = 0.0125 μg/mL) (MFC = 0.0125 μg/mL), Cryptococcus neoformans (CGMCC 2.3161) (MIC₈₀ = 0.0125 μg/mL) (MFC = 0.0625 μg/mL) and Aspergillus fumigatus (CGMCC 3.7795) (MIC₈₀ = 0.025 μg/mL)^[1].
CYP51-IN-25 has a lower risk of drug-drug interactions (DDI) in other CYP450 isoforms such as CYP1A2 (IC₅₀ > 10 μg/mL), CYP2C9 (IC₅₀ = 1.76 μg/mL), CYP2C19 (IC₅₀ = 1.71 μg/mL), CYP2D6 (IC₅₀ > 10 μg/mL), CYP3A4-M (IC₅₀ = 5.11 μg/mL) and CYP3A4-T (IC₅₀ = 6.62 μg/mL)^[1].
CYP51-IN-25 maintains a favorable safety profile toward mammalian cells within the tested concentration range^[1].
CYP51-IN-25 inhibits the biofilm formation of Candida glabrata (SMIC₅₀ = 0.0625 μg/mL) and Cryptococcus neoformans (CGMCC 2.3161) (SMIC₅₀ = 0.1625 μg/mL)^[1].
CYP51-IN-25 (2 μg/mL) effectively inhibits the transformation of fungi from yeast phase to hyphal phase^[1].
CYP51-IN-25 (16 μg/mL,48 h) destroys the integrity of fungal cell membranes of Candida albicans (SC 5314)^[1].
CYP51-IN-25 (0.0125-0.125 μg/mL) can significantly reduce the content of ergosterol of Candida albicans (SC 5314) and Cryptococcus neoformans (CGMCC 2.3161)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.